基于 microRNA 的慢性乙型和丙型肝炎患者肝纤维化和肝硬化的诊断工具。
MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C.
机构信息
INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l'Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France.
Service d'hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France.
出版信息
Sci Rep. 2016 Oct 12;6:34935. doi: 10.1038/srep34935.
Staging fibrosis is crucial for the prognosis and to determine the rapid need of treatment in patients with chronic hepatitis B (CHB) and C (CHC). The expression of 13 fibrosis-related microRNAs (miRNAs) (miR-20a, miR-21, miR-27a, miR-27b, miR-29a, miR-29c, miR-92a, miR-122, miR-146a, miR-155, miR-221, miR-222, and miR-224) was analyzed in 194 serums and 177 liver biopsies of patients with either CHB or CHC to develop models to diagnose advanced fibrosis and cirrhosis (Metavir F3-F4). In CHB patients, the model (serum miR-122, serum miR-222, platelet count and alkaline phosphatase) was more accurate than APRI and FIB-4 to discriminate in between mild and moderate fibrosis (F1-F2) and F3-F4 (AUC of CHB model: 0.85 vs APRI: 0.70 and FIB-4: 0.81). In CHC patients, the model (hepatic miR-122, hepatic miR-224, platelet count, albumin and alanine aminotransferase) was more accurate than both APRI and FIB-4 to discriminate in between patients with F3-F4 and F1-F2 (AUC of the CHC model = 0.93 vs APRI: 0.86 and FIB-4: 0.79). Most of the miRNAs tested were differentially expressed in patients with CHB and CHC. In particular, serum miR-122 was 28-fold higher in patients with CHB than in those with CHC. Both CHB and CHC models may help for the diagnosis of advanced fibrosis and cirrhosis (F3-F4).
对慢性乙型肝炎（CHB）和丙型肝炎（CHC）患者进行纤维化分期对于预后评估和确定治疗的迫切需求至关重要。在 194 例 CHB 患者和 177 例 CHC 患者的血清和肝组织活检中分析了 13 种纤维化相关 microRNAs（miRNAs）（miR-20a、miR-21、miR-27a、miR-27b、miR-29a、miR-29c、miR-92a、miR-122、miR-146a、miR-155、miR-221、miR-222 和 miR-224）的表达，以开发用于诊断晚期纤维化和肝硬化（Metavir F3-F4）的模型。在 CHB 患者中，与 APRI 和 FIB-4 相比，该模型（血清 miR-122、血清 miR-222、血小板计数和碱性磷酸酶）更能准确地区分轻度和中度纤维化（F1-F2）与 F3-F4（CHB 模型的 AUC：0.85 vs APRI：0.70 和 FIB-4：0.81）。在 CHC 患者中，与 APRI 和 FIB-4 相比，该模型（肝 miR-122、肝 miR-224、血小板计数、白蛋白和丙氨酸氨基转移酶）更能准确地区分 F3-F4 与 F1-F2 的患者（CHC 模型的 AUC = 0.93 vs APRI：0.86 和 FIB-4：0.79）。在 CHB 和 CHC 患者中，大多数测试的 miRNAs 表达水平不同。特别是，血清 miR-122 在 CHB 患者中比 CHC 患者高 28 倍。CHB 和 CHC 模型都可能有助于诊断晚期纤维化和肝硬化（F3-F4）。
Zotero 插件